J9317 CPT Code: A Complete Billing and Reimbursement Guide for 2026

If you work in medical billing or oncology, you have likely come across the J9317 code on a fee schedule or a claim form.

You might be wondering if it is the right code for a specific drug. Or perhaps you are trying to figure out why your previous claim got denied.

Let us clear up the confusion.

The J9317 code is a specific HCPCS (Healthcare Common Procedure Coding System) code. It is not a random set of letters and numbers. It represents a very specific medication used primarily in cancer care.

In this guide, we will break down everything you need to know. We will look at what the drug is, how to bill it, what the common pitfalls are, and how much reimbursement you can realistically expect.

We will keep the language simple and the advice practical.

What Exactly Is the J9317 CPT Code?

First, a quick clarification. Many people call it a “CPT code,” but technically, J-codes fall under the HCPCS Level II system. CPT codes usually describe procedures and services. HCPCS Level II codes describe products, supplies, and drugs.

The J9317 code is specifically used for Rituximab-abbs.

You might recognize the name. Rituximab is a well-known biologic medication. It is a monoclonal antibody that targets CD20-positive B-cells. In simple terms, it helps the immune system fight certain types of cancer and autoimmune diseases.

The version represented by J9317 is the biosimilar product.

Generic Name: Rituximab-abbs
Brand Name: Truxima®
Route of Administration: Intravenous (IV) infusion

It is essential to note that this is not the reference product Rituxan (which uses code J9312). It is also not the subcutaneous version. Getting this distinction correct is critical for clean claims.

When Is J9317 Used?

Providers use this code when they administer the biosimilar rituximab-abbs to a patient in an outpatient setting. This includes:

Hospital outpatient departments
Oncology clinics
Infusion centers
Nephrology clinics (for certain autoimmune conditions)

Clinical Indications for the Drug

The medication linked to J9317 is not a simple painkiller or antibiotic. It is a potent immunotherapy. Doctors typically prescribe it for:

Non-Hodgkin’s Lymphoma (NHL): Specifically for CD20-positive B-cell lymphomas.
Chronic Lymphocytic Leukemia (CLL): As part of combination therapy.
Rheumatoid Arthritis (RA): For patients who have not responded well to TNF antagonist therapies.
Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA): In combination with glucocorticoids.

Because it suppresses the immune system, this medication requires careful monitoring.

J9317 vs. Other Rituximab Codes: A Critical Comparison

This is where most billing errors happen. You cannot use different rituximab codes interchangeably. Payers will deny your claim immediately if you use the wrong code, even if the clinical notes are correct.

Here is a simple table to help you avoid that mistake.

HCPCS Code	Drug Name	Type	Key Note
J9317	Rituximab-abbs (Truxima)	Biosimilar	Use exclusively for this biosimilar.
J9312	Rituximab (Rituxan)	Reference Product	Original biologic. Different NDC.
J9311	Rituximab-pvvr (Ruxience)	Biosimilar	Another biosimilar option.
J9310	Rituximab, 100 mg (Rituxan – legacy)	Reference Product	Old code. Discontinued for most payers.

Important Note for readers: Always verify the National Drug Code (NDC) on your vial before billing. The NDC for J9317 (Truxima) is different from Rituxan or Ruxience. If your invoice says one drug but you bill another code, that is a compliance red flag.

How to Bill for J9317 Correctly (Step-by-Step)

Billing for biologic infusions requires more than just slapping a code on a form. You need a combination of codes: one for the drug itself (J9317) and others for the administration.

The Drug Code (J9317)

This code is typically billed per unit. The standard dosage unit for J9317 is 10 mg.

Most vials of rituximab-abbs come in 100 mg/10 mL and 500 mg/50 mL single-dose vials.

If a patient receives a 500 mg infusion, you calculate the units as follows:

500 mg / 10 mg per unit = 50 units.
You would bill 50 units of J9317.

The Administration Codes

You cannot just bill J9317. You also need to bill for the nurse’s time, the IV setup, and the monitoring. The specific CPT codes for infusion administration depend on the time and complexity.

Here is a typical sequence for a first-time infusion:

CPT 96365: Intravenous infusion, for therapy, prophylaxis, or diagnosis (initial up to 1 hour).
CPT 96366: Each additional hour of infusion (used for subsequent hours).
CPT 96367: Concurrent infusion (if another drug is infused simultaneously in a separate IV site).
CPT 96372: Therapeutic, prophylactic, or diagnostic injection (for a pre-medication push like diphenhydramine).

Pre-Medicating the Patient

Before administering rituximab-abbs, patients almost always receive pre-medications. These reduce the risk of infusion-related reactions. Common pre-meds include:

Acetaminophen (oral)
Antihistamine (e.g., diphenhydramine IV or oral)
Glucocorticoid (e.g., methylprednisolone IV)

These pre-meds are separate services. You will usually bill them under the appropriate J-codes (like J2550 for methylprednisolone) plus the injection administration code (96372).

Reimbursement Rates for J9317 in 2026

This is the question everyone wants to answer: How much money will I get paid?

The honest answer is: it depends on your payer.

Medicare sets a base rate, but private insurers, Medicare Advantage plans, and Medicaid programs all have different fee schedules.

Medicare Payment Calculation

Medicare pays for most J-codes under the Average Sales Price (ASP) methodology. The reimbursement is ASP + 6% (which covers overhead and wastage).

As of the latest 2026 fee schedule updates (preliminary data), the ASP for rituximab-abbs is competitive with other biosimilars. The exact rate fluctuates quarterly.

To give you a realistic estimate:

If the ASP for a 10 mg unit is $10.50, M e d i c a r e p a y s$ 10.50,Medicarepays11.13 (including the 6% add-on).
For a standard 500 mg infusion (50 units), the drug cost would be approximately $556.50.

Do not forget the wastage rule. You can bill for leftover drug in a single-dose vial that is discarded, provided you document it. If you use a 500 mg vial but only need 420 mg, you can bill for the full 500 mg. You cannot, however, combine two partial vials from different patients to avoid waste.

Private Payer Rates

Private insurance companies often negotiate rates. They might pay:

Percentage of AWP (Average Wholesale Price): Typically 80% to 85% of AWP minus a discount.
Case rates: A flat fee for the entire infusion visit.
Contract rates: A specific dollar amount per unit.

Quote from a billing manager at a Midwest oncology clinic: “We see anywhere from $9.00 t o$ 9.00to14.00 per unit for J9317 depending on the insurance. The biggest delays happen when we bill the wrong NDC. Always double-check your NDC before submitting.”

Common Denial Reasons for J9317 and How to Fix Them

Even experienced billers get denials. Let us look at the most frequent issues with J9317 claims.

1. Mismatched Code and NDC

This is the number one error. You bill J9317, but the NDC you enter on the claim line belongs to Rituxan or Ruxience.

How to fix it: Match the first 11 digits of the NDC exactly to the drug you administered. Train your staff to scan the vial barcode and verify the NDC against the HCPCS code crosswalk.

2. Incorrect Units

Remember: J9317 = 10 mg. If you accidentally treat it as 100 mg per unit, you will overbill by 1,000%.

How to fix it: Use a billing calculator. For every 10 mg of drug, bill 1 unit. Double-check your math before submitting the claim.

3. Missing Diagnosis Linkage

Rituximab-abbs is not for every condition. If you link the claim to a diagnosis like “unspecified fever” or “general weakness,” the payer will deny it for medical necessity.

How to fix it: Ensure the ICD-10 code on the claim is one of the approved indications. Use codes like:

C83.xx (Non-Hodgkin lymphoma)
C91.1x (Chronic lymphocytic leukemia)
M05.xx (Rheumatoid arthritis with rheumatoid factor)

4. No Pre-Authorization

Many commercial payers require prior authorization for biologic drugs. If you skip this step, you will receive a denial.

How to fix it: Create a checklist. Before scheduling the infusion, confirm that the authorization is on file and matches the exact drug name (Truxima) and the J9317 code.

Documentation Requirements for J9317

Good documentation protects you during an audit. If a payer or Medicare requests medical records, you need to prove that the service was medically necessary and correctly billed.

Your record must include:

Physician order: Signed and dated. It should specify “Rituximab-abbs (Truxima)” with the dose in mg.
Administration record: Shows the start and stop time of the infusion, the IV site, the flow rate, and any reactions.
Drug lot number and NDC: This proves which product you used.
Weight-based dose calculation: Most rituximab doses are based on body surface area (BSA). Keep the calculation in the chart.
Pre-medication record: Evidence that the patient received pre-meds to prevent infusion reactions.

The Role of J9317 in Value-Based Care

The healthcare system is moving away from fee-for-service and toward value-based care. Biosimilars like the one billed with J9317 are a big part of this shift.

Biosimilars are nearly identical copies of expensive biologic drugs. They come to the market at a lower cost. This helps:

Reduce patient out-of-pocket expenses.
Lower the total cost of care for payers.
Increase patient access to effective treatments.

When you use J9317 instead of a more expensive reference product, you are often aligned with payer incentives. Some insurance contracts even offer bonuses or shared savings for using biosimilars.

Step-by-Step Checklist for Clean J9317 Claims

To make your life easier, here is a simple checklist to run through before you hit “submit” on your claim.

Verify the medication name on the vial: Rituximab-abbs (Truxima).
Confirm the NDC matches the J9317 crosswalk.
Calculate units correctly (total mg ÷ 10 = units).
Add the appropriate administration code (96365, 96366).
Link the J9317 line to a valid, covered ICD-10 diagnosis.
Check that prior authorization is on file (for commercial payers).
Document any wastage on the record.
Include the discard fee if your contract allows it (QJ code for Part B? Check local policy).

Frequently Asked Questions (FAQ)

1. Can I bill J9317 for a patient who is enrolled in a clinical trial?
Usually, no. In most clinical trials, the sponsor pays for the investigational drug. However, if the trial uses a standard-of-care biosimilar, you might bill routine costs to insurance. Always check the trial contract first.

2. What happens if I accidentally bill J9312 instead of J9317?
The payer will likely deny the claim. You will need to submit a corrected claim with the correct code. This can delay payment by 30 to 90 days.

3. Is J9317 only for cancer?
No. While it is heavily used in oncology, it is also approved for rheumatoid arthritis and two forms of vasculitis (GPA and MPA).

4. How do I bill for the infusion if the patient has a reaction and I stop early?
Bill for the time you actually infused. Do not bill for the planned time. Use modifier -52 (reduced services) for the administration code if the time was significantly shorter.

5. Does Medicare cover J9317?
Yes. Medicare Part B covers rituximab-abbs for medically necessary indications. Coverage follows the National Coverage Determination (NCD) for monoclonal antibodies.

6. What is the difference between J9317 and Q5121?
Q5121 is another code for a rituximab biosimilar (Riabni). They are different products. Never substitute one code for another.

Additional Resources

For the most current fee schedules and NDC to HCPCS crosswalks, bookmark these official sources:

CMS HCPCS Quarterly Update: https://www.cms.gov/medicare/coding-billing/hcpcs-quarterly-updates (Visit the official CMS website for the latest files)
FDA Purple Book: Lists approved biosimilars and their reference products for regulatory clarity.

Is It Time to Switch to J9317 in Your Practice?

If you are currently using a different rituximab product, you might be asking: Should I switch to the biosimilar billed with J9317?

The decision is usually financial and contractual.

If your payer contracts favor biosimilars, switching saves money.
If your patients have high co-insurance, a lower-cost biosimilar reduces their financial burden.

However, always check with your medical director before switching a patient’s biologic. In oncology, consistency matters. Switching products mid-treatment is generally safe for biosimilars, but the clinical team should be aware.

Final Thoughts on Mastering the J9317 Code

The J9317 code does not have to be a headache. It is simply a tool. When you understand what it represents, how to calculate it, and how to document it, the code becomes just another routine part of your workflow.

The most common mistakes—wrong NDC, wrong units, and missing auth—are all avoidable. Put a second set of eyes on every claim that includes J9317. Train your intake staff to verify the drug name at the moment of ordering.

Biosimilars are the future of biologic therapy. Mastering codes like J9317 now means your practice will be ready for the next wave of cost-effective, high-quality treatments.

Conclusion

The J9317 CPT code is used to bill for the biosimilar rituximab-abbs (Truxima) in 10 mg increments for intravenous infusion. Correct billing requires accurate unit calculation, proper administration codes, and precise NDC matching to avoid denials. By following the documentation and payer-specific guidelines in this guide, you can ensure compliant reimbursement and reduce claim rejections.

J9317 CPT Code: A Complete Billing and Reimbursement Guide for 2026